Influence of dialysis membranes on interleukin-1β and interleukin-1 receptor antagonist production by peripheral blood mononuclear cells

Artificial Organs

Volumn 21, Issue 4, 1997, Pages 265-271

  Higuchi, Terumi ^a   Kuno, Tsutomu ^a   Takahashi, Susumu ^a   Kanmatsuse, Katsuo ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Biocompatibility; Dialysis membrane; Interleukin 1 receptor antagonist; Interleukin 1 ; Peripheral blood mononuclear cells

Indexed keywords

BIOCOMPATIBILITY; BLOOD; CELLS; CYTOLOGY; DIALYSIS MEMBRANES;

CELLULAR CONTENT; CELLULOSE MEMBRANES; HAEMODIALYSIS; IN-VITRO; INTERLEUKIN 1Β; INTERLEUKIN-1 RECEPTOR ANTAGONISTS; LIPOPOLYSACCHARIDES; PERIPHERAL BLOOD MONONUCLEAR CELLS; POLYSULPHONE; REGENERATED CELLULOSE;

DIALYSIS;

AN 69; CELLULOSE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; POLYAMIDE; POLYSULFONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BIOCOMPATIBILITY; BLOOD; CLINICAL ARTICLE; DIALYSIS MEMBRANE; FEMALE; HEMODIALYSIS; HUMAN; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL;

EID: 0030995161     PISSN: 0160564X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-1594.1997.tb00360.x     Document Type: Article

References (32)

1. Henderson LW, Koch KM, Dinarello CA, Shaldon S. Hemodialysis hypotension: The interleukin hypothesis. Blood Purif 1983;1:3-8.
2. Dinarello CA. Cytokines agents provocateurs in hemodialysis? Kidney Int 1992;41:683-94.
3. Herbelin A, Nguyen AT, Zingraff J, Urena P, Descamp-Latscha B. Influence of uremia and hemodialysis on circulating interleukin-1 and tumor necrosis factor α. Kidney Int 1990; 37:116-25.
4. Herbelin A, Urena P, Nguyen AT, Zingraff J, Descamp-Latscha B. Elevated circulating levels of interleukin-6 in patients with chronic renal failure. Kidney Int 1991;39:954-60.
5. Luger A, Kovarik J, Stummvoll HK, Urbanska A, Luger TA. Blood-membrane interaction in hemodialysis leads to increased cytokine production. Kidney Int 1987;32:84-8.
6. Lonnemann G, Van Deer Meer JWM, Cannon JG, Dinarello CA, Koch KM, Granolleras C, Deschodt G, Shaldon S. Induction of tumor necrosis factor during extracorporeal blood purification. N Engl J Med 1987;317:963-4.
7. Seckinger P, Lowenthal JW, Williamson K, Dayer JM, Macdonald HR. A urine inhibitor of interleukin-1 activity that blocks ligand binding. J Immunol 1987;139:1546-9.
8. Pereira BJG, Poutsiaka DD, Strom JA, Narayan G, Levey AS, King AJ, Dinarello CA. In vitro production of interleukin-1 receptor antagonist in chronic renal failure. CAPD, and HD. Kidney Int 1992;42:1419-24.
9. Pereira BJG, Shapiro L, King AJ, Falagas ME, Strom JA, Dinarello CA. Plasma levels of IL-1β, TNF α and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients. Kidney Int 1994;45:890-6.
10. Chenoweth DE, Cheung AK, Henderson LW. Anaphylatoxin formation during hemodialysis: Effects of different dialyzer membranes. Kidney Int 1983;24:764-9.
11. Hakim PM, Fearon DT, Lazarus MJ. Biocompatibility of dialysis membranes: effects of chronic complement activation. Kidney Int 1984;26:194-200.
12. Heidland A, Horl WH, Heller N, Heine H, Neumann S, Heidbreder E. Proteolytic enzymes and catabolism: Enhanced release of granulocyte proteinases in uremic intoxication and during hemodialysis. Kidney Int 1983;24:16-27.
13. Horl WH, Schaefer RM, Heidland A. Effect of different dialyzers on proteinase inhibitors during hemodialysis. Am J Nephrol 1985;5:320-6.
14. Teta C, Camussi G, Turello E, Salomone M, Aimo G, Priolo G, Segoloni G, Vercellone A. Production of cytokines during hemodialysis. Blood Purif 1990;8:337-46.
15. Haeffner-Cavaillon N, Cavaillon JM, Ciancioni C, Bacle F, Delons S, Kazatchkine MD. In vivo induction of interleukin-1 during hemodialysis. Kidney Int 1989;35:1212-8.
16. Schindler R, Linnenweber S, Schulze M, Oppermann M, Dinarello CA, Shaldon S, Koch KM. Gene expression of interleukin 1β during hemodialysis. Kidney Int 1993;43:712-21.
17. Chatenoud L, Dugas B, Beaurain G, Touam M, Drueke T, Vasquez A, Galanaud P, Bach JF, Delfraissy JF. Presence of preactivated T cells in hemodialyzed patients: Their possible role in altered immunity. Proc Natl Acad Sci USA 1986;83: 7457-61.
18. Beaurain G, Naret C, Marcon L, Grateau G, Drucke T, Urena P, Nelson DL, Bach JF, Chatenoud L. In vivo T cell preactivation in chronic uremic hemodialyzed and nonhemodialyzed patients. Kidney Int 1989;36:636-44.
19. Foret M, Hachache T, Meftahi H, Milongo R, Kuentz F, Christollet M, Alibeu C, Cordonnier DJ. The long-term evaluation of the biocompatibility of nine different haemodialysis membranes. Life Support Systems 1987;5:203-6.
20. Schafer RM, Oilge U, Gohl H, Heiland A. Evaluation of a new polyamide membrane (polyflux 130) in high-flux dialysis. Blood Purif 1990;8:23-31.
21. Chenoweth DE. Complement activation during hemodialysis: clinical observations, proposed mechanisms, and theoretical implications. Artif Organs 1984;3:281-7.
22. Jorstad S, Smeby LC, Balstad T, Wideroe TE. Generation and removal of anaphylatoxins during hemofiltration with five different membranes. Blood Purif 1988;6:325-35.
23. Pereira BJG, King AJ, Poutsiaka DD, Strom JA, Dinarello CA. Comparison of first use and reuse of cuprophan membranes on interleukin-1 receptor antagonist and interleukin-1β production by blood mononuclear cells. Am J Kidney Dis 1993;22:288-95.
24. Engelberts I, Fancot GJM, Leunissen KML, Haenen B, Ceska M, Linden CJ, Buurman WA. Effect of hemodialysis on peripheral blood monocyte tumor necrosis factor α interleukin 6, and interleukin 8 secretion in vitro. Nephron 1994;66: 396-403.
25. Fisher E, Marano MA, Barber AE, Hudson A, Lee K, Rock CS, Hawes AS, Thompson RC, Hayes TJ, Anderson TD, Benjamin WR, Lowry SF, Moldawer LL. Comparison between effects of interleukin-ra administration and sublethal endotoxemia in primates. Am J Physiol 1991;261:R442-52.
26. Granowitz EV, Santos A, Poutsiaka DD, Cannon JG, Wilmore DA, Dinarello CA. Circulating interleukin-1 receptor antagonist levels during experimental endotoxemia in humans. Lancet 1991;338:1423-4.
27. Arend WP, Welgus HG, Thompson RC, Eisenberg SP. Biological properties of recombinant human monocyte-derived interleukin-1 receptor antagonist. J Clin Invest 1990;85: 1694-7.
28. McIntyre KW, Stepan GJ, Kolinsky DK, Benjamín WR, Plocinski JM, Kaffka KL, Campen RA, Chizzonite RA, Kilian PL. Interleukin-1 receptor antagonist blocks acute inflammatory response to IL-1 and other agents in vitro. J Exp Med 1991;173:931-9.
29. Dinarello CA. Interleukin-1 and interleukin-1 antagonism. Blood 1991;77:1627-52.
30. Haeffner-Cavillon N, Jahns G, Poignet JL, Kazatchkine M. Induction of interleukin-1 during hemodialysis. Kidney Int 1993;43 (Suppl 39):139-43.
31. Ghysen J, De Plaen JF, zan Ypersle de Strihou C. The effect of membrane characteristics on tumour necrosis factor kinetics during hemodialysis. Nephrol Dial Transplant 1990;5: 270-4.
32. Canivet E, Lavaud S, Wong T, Guenounou M, Willemin JC, Potron G, Chanard J. Cuprophane but not synthetic membrane induces increases in serum tumor necrosis factor-alpha levels during hemodialysis. Am J Kidney Dis 1994;23:41-6.